For example, phase 2 trials are ongoing (NCT00753545) using PARP inhibitor Olaparib in patients with ovarian cancer that recurred within 12 months of prior platinum therapy, with confirmed germline BRCA1/BRCA2 mutation. This evidence concerns the gene PARP1 and ovarian cancer.